Cargando…
Review of Evidence Supporting 2022 US Food and Drug Administration Drug Approvals
This cross-sectional study examines the design and funding of studies, nd evidence available on ClinicalTrials.gov for drugs approved in 2022.
Autores principales: | Kaplan, Robert M., Koong, Amanda J., Irvin, Veronica |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10410475/ https://www.ncbi.nlm.nih.gov/pubmed/37552481 http://dx.doi.org/10.1001/jamanetworkopen.2023.27650 |
Ejemplares similares
-
Analysis of Supportive Evidence for US Food and Drug Administration Approvals of Novel Drugs in 2020
por: Mitra-Majumdar, Mayookha, et al.
Publicado: (2022) -
Characteristics of Recent Generic Drug Approvals by the US Food and Drug Administration
por: Jiao, Kuo, et al.
Publicado: (2019) -
A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022
por: Kayki-Mutlu, Gizem, et al.
Publicado: (2023) -
Evaluation of Representation of Women as Authors in Pivotal Trials Supporting US Food and Drug Administration Approval of Novel Cardiovascular Drugs
por: Shahid, Izza, et al.
Publicado: (2022) -
Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval
por: Parikh, Ravi B., et al.
Publicado: (2023)